Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...
Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...
Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who Took Bempedoic Acid Were 36% Less Likely To Experience A Major Adverse Limb Event Compared To Placebo
Esperion在2024年美國心臟協會（AHA）科學會議的特色科學會議和多個海報展示中，強調了CLEAR Outcomes試驗中關於NEXLETOL的新探索性數據；探索性分析報告顯示，與安慰劑相比，服用苯溴馬隆的外周動脈疾病（PAD）患者發生重大不良肢體事件的可能性降低了36%。
– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo –
—— 一項探索性分析報告顯示，與安慰劑相比，服用苯溴馬隆的外周動脈疾病（PAD）患者發生重大不良肢體事件的可能性降低了36% ——
ANN ARBOR, Mich., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the presentation of an analysis from the CLEAR Outcomes study focused on patients with Peripheral Artery Disease (PAD) who were unable or unwilling to take statin medications. These data were presented today in an oral featured science presentation at the 2024 American Heart Association (AHA) Scientific Sessions, which took place from November 16-18, 2024, in Chicago, IL. Additionally, two exploratory analyses from the CLEAR Outcomes trial and a real-world analysis of bempedoic acid usage were presented at the conference.
美國密歇根州安阿伯，2024年11月18日（環球新聞稿）——Esperion（納斯達克：ESPR）今天宣佈了關於CLEAR Outcomes研究的一個分析，該研究集中於無法或不願意服用他汀藥物的外周動脈疾病（PAD）患者。這些數據於2024年美國心臟協會（AHA）科學會議上以口頭特色科學展示的形式進行了呈現，該會議於2024年11月16日至18日在伊利諾伊州芝加哥舉行。此外，還在會議上展示了CLEAR Outcomes試驗的兩項探索性分析和苯溴馬隆使用的現實世界分析。
